Takeda Canada Innovation Challenge Awarded to Pentavere to Accelerate Rare Disease Diagnosis and Care Using New AI Technology & More News Here

FOR CANADIAN AUDIENCES ONLY

• Toronto-based Pentavere will collaborate with Takeda Canada and obtain devoted funding for brand new proof-of-concept AI undertaking centered on Rare Disease care

• Innovation Challenge was launched to discover new companions and establish breakthrough concepts to assist developments in Rare Disease diagnoses by means of AI expertise

• Investment will assist Rare Disease Real-World Evidence (RWE) evaluation throughout Canada

TORONTO, May 11, 2022 /CNW/ – Takeda Canada Inc. is happy to announce Pentavere Research Group Inc. has been awarded the primary Takeda Canada Innovation Challenge. The Innovation Challenge was launched in January 2022 to speed up partnerships in figuring out new digital applied sciences and synthetic intelligence (AI) options that assist enhanced affected person care in inflammatory bowel illness (IBD) or uncommon illness situations.

Pentavere Research Group Inc. is a medical discovery firm that has developed a breakthrough, proprietary, synthetic intelligence (AI) engine known as DARWEN™, which accelerates discovery from huge quantities of medical textual content. DARWEN™ unlocks worth, insights and proof from medical info which is inconceivable to analyze by human intelligence alone.

“We are thrilled to have the opportunity to collaborate with Pentavere to leverage their AI technology within the field of rare diseases,” mentioned Rute Fernandes, General Manager, Takeda Canada. “Building strong partnerships across our healthcare ecosystem and leveraging data and technology is imperative to holistically address key patient needs, from diagnostics right through to personalized medicine. We would like to congratulate Pentavere on its successful submission and to thank all entrants for participating in the Takeda Canada Innovation Challenge.”

Pentavere may have the chance to collaborate and profit from Takeda’s experience and in depth worldwide community, in addition to funding, to construct a proof of idea undertaking within the areas of uncommon ailments.

Story continues

“Our team is incredibly excited to learn that Pentavere and our AI engine, DARWEN™, have been selected as the winning submission in the Takeda Canada Innovation Challenge,” mentioned Aaron Leibtag, Co-Founder and CEO, Pentavere Research Group. “We are delighted to be collaborating with Takeda Canada and to be working with its team of experts to unlock the knowledge buried in millions of pages of clinical information. Together we will be generating the data, insights and breakthrough solutions we need to improve the lives of patients living with rare diseases. We would like to thank Takeda Canada for this opportunity and its ongoing commitment to investing in Canadian innovation that can scale globally.”

The Takeda Canada Innovation Challenge obtained a number of submissions inside the fields of early prognosis or built-in and personalised care, relevant to the therapeutic areas of inflammatory bowel illness (ulcerative colitis or Crohn’s illness) or uncommon genetic ailments.

“We could not be more pleased with the number of quality submissions that this important initiative received,” mentioned Dr. Jefferson Tea, Vice President, Medical and Scientific Affairs, Takeda Canada. “Takeda firmly believes that partnering with others is essential to identify and continuously explore new options to support patients at every step through their journey.

About Takeda Canada Inc.

Takeda Canada Inc. is the Canadian organization of Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK), a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit: takeda.com/en-ca

SOURCE Takeda Canada Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2022/11/c8563.html

I have tried to give all kinds of news to all of you latest news today 2022 through this website and you are going to like all this news very much because all the news we always give in this news is always there. It is on trending topic and whatever the latest news was

it was always our effort to reach you that you keep getting the latest news and you always keep getting the information of news through us for free and also tell you people. Give that whatever information related to other types of news will be

made available to all of you so that you are always connected with the news, stay ahead in the matter and keep getting today news all types of news for free till today so that you can get the news by getting it. Always take two steps forward